TPST (Tempest Therapeutics) Interest Received


TPST Tempest Therapeutics Inc TPST
32 GF Score
Price $1.12
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

TPST
32GF Score
Tempest Therapeutics Inc TPST
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for TPST

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price